Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).

被引：0
|
作者：
Leong, Sally
Ali, Sana
Zengin, Zeynep Busra
Meza, Luis A.
Dizman, Nazli
Ebrahimi, Hedyeh
Govindarajan, Ameish
Castro, Daniela V.
Li, Xiaochen
Kim, Tane
Melamed, Sam
Pal, Sumanta Monty
Chehrazi-Raffle, Alex
机构：
[1] Harbor UCLA Med Ctr, Torrance, CA USA
[2] City Hope Comprehens Canc Ctr, Duarte, CA USA
[3] Lundquist Res Inst, Torrance, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
613
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Yoshino, Maki
    Ishihara, Hiroki
    Nemoto, Yuki
    Nakamura, Kazutaka
    Nishimura, Koichi
    Tachibana, Hidekazu
    Fukuda, Hironori
    Toki, Daisuke
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Tanabe, Kazunari
    Kondo, Tsunenori
    Takagi, Toshio
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (10) : 1208 - 1214
  • [32] POTENTIAL SURVIVAL BENEFIT OF DEFERRED NEPHRECTOMY IN PATIENTS TREATED WITH NIVOLUMAB PLUS IPILIMUMAB FOR METASTATIC RENAL CELL CARCINOMA
    Yoshino, Maki
    Ishihara, Hiroki
    Nemoto, Yuki
    Nakamura, Kazutaka
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Hiroaki, Shimmura
    Hashimoto, Yasunobu
    Takagi, Toshio
    Kondo, Tsunenori
    Tanabe, Kazunari
    JOURNAL OF UROLOGY, 2022, 207 (05): : E170 - E170
  • [33] Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
    Gan, Chun Loo
    Wells, J. Connor
    Schmidt, Andrew Lachlan
    Powles, Thomas
    Tran, Ben
    Meza, Luis A.
    Labaki, Chris
    Lee, Jae-Lyun
    Wood, Lori
    Shapiro, Julia
    Ernst, D. Scott
    Kapoor, Anil
    Canil, Christina M.
    Yuasa, Takeshi
    McKay, Rana R.
    Beuselinck, Benoit
    Donskov, Frede
    Dudani, Shaan
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Kim, Jwa Hoon
    Kim, Gi Hwan
    Ryu, Yeon-Mi
    Kim, Sang-Yeob
    Kim, Hyung-Don
    Yoon, Shin Kyo
    Cho, Yong Mee
    Lee, Jae Lyun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
    Numakura, Kazuyuki
    Sekine, Yuya
    Hatakeyama, Shingo
    Muto, Yumina
    Sobu, Ryuta
    Kobayashi, Mizuki
    Sasagawa, Hajime
    Kashima, Soki
    Yamamto, Ryohei
    Nara, Taketoshi
    Akashi, Hideo
    Tabata, Ryuji
    Sato, Satoshi
    Saito, Mitsuru
    Narita, Shintaro
    Ohyama, Chikara
    Habuchi, Tomonori
    CANCER MEDICINE, 2023, 12 (16): : 16837 - 16845
  • [36] Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO plus IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.
    Tannir, Nizar M.
    Motzer, Robert J.
    Albiges, Laurence
    Plimack, Elizabeth R.
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Rini, Brian, I
    Grunwald, Viktor
    Hammers, Hans J.
    Choueiri, Toni K.
    Gurney, Howard
    Tykodi, Scott S.
    Porta, Camillo
    Burotto, Mauricio
    Tomita, Yoshihiko
    Lee, Chung-Wei
    Tang, Chad
    McDermott, David F.
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [37] Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy
    Takagi, Toshio
    Yoshida, Kazuhiko
    Kondo, Tsunenori
    Fukuda, Hironori
    Ishihara, Hiroki
    Kobayashi, Hirohito
    Iizuka, Junpei
    Ishida, Hideki
    Tanabe, Kazunari
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (12) : 1744 - 1750
  • [38] A retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with Ipilimumab and Nivolumab
    Brown, Landon
    Kinsey, Emily
    Kao, Chester
    Healy, Patrick
    Armstrong, Andrew
    McNamara, Megan
    Ramalingam, Sundhar
    Harrision, Michael
    George, Daniel
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [39] CLINICAL IMPLICATIONS AND PREDICTIVE FACTORS OF PRIMARY RESISTANCE TO NIVOLUMAB PLUS IPILIMUMAB THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Numakura, Kazuyuki
    Hatakeyama, Shingo
    Sekine, Yuya
    Yumina, Muto
    Kobayashi, Mizuki
    Kashima, Soki
    Yamamoto, Ryohei
    Nara, Taketoshi
    Saito, Mitsuru
    Narita, Shintaro
    Ohyama, Chikara
    Habuchi, Tomonori
    JOURNAL OF UROLOGY, 2023, 209 : E371 - E372
  • [40] Predictive factors of nivolumab plus ipilimumab treatment efficacy in metastatic renal cell carcinoma patients
    Ohba, Kojiro
    Nakanishi, Hiromi
    Kawada, Ken
    Nakamura, Yuichiro
    Mitsunari, Kensuke
    Matsuo, Tomohiro
    Mochizuki, Yasushi
    Imamura, Ryoichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (07) : 827 - 832
12345